transform-1: navitoclax ruxolitinib vs placebo ruxolitinib in patients with untreated mf
Published 9 months ago • 149 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
2:06
the promise of combining navitoclax and ruxolitinib in mf
-
2:12
refine: phase ii study of navitoclax ruxolitinib in jak inhibitor-naive patients with mf
-
1:18
novel approaches for the treatment of myelofibrosis: navitoclax ruxolitinib
-
3:39
efficacy of navitoclax with ruxolitinib in myelofibrosis patients
-
1:57
combined navitoclax and ruxolitinib therapy in r/r myelofibrosis
-
2:10
phase i study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
-
1:16
the rationale for combining magrolimab with ruxolitinib in myelofibrosis
-
8:03
phase ii trial of navitoclax and ruxolitinib in high-risk r/r myelofibrosis
-
7:16
developing a mouse model to elucidate the molecular mechanisms of richter's transformation
-
4:34
development and evaluation of a novel car-t cell therapy against calr mutant neoplasms
-
5:19
the current treatment landscape for multiple myeloma and trials investigating novel combinations
-
1:39
refine: updated data on navitoclax and ruxolitinib for myelofibrosis
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
3:44
phase ii study update of navtemadlin in patients with myelofibrosis r/r to ruxolitinib
-
1:26
phase i trial of copanlisib nivolumab in patients with richter’s transformation or transformed fl
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
2:39
a phase ii trial of ruxolitinib and azacitidine combination therapy in patients with myelofibrosis
-
3:49
manifest: pelabresib (cpi-0610) ruxolitinib in advanced myelofibrosis patients
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
3:02
euplagia-1: phase i trial of glpg5201, a cd19 car-t product, in r/r cll and richter's transformation
-
2:17
epcore cll-1: epcoritamab in patients with r/r cll & richter's transformation